Medicare AdvantageCoverageMedium impact
MA06.036, Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Independence Blue Cross·Urology, Oncology, Family Medicine +1 more·Medical Policy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.036 regarding protein biomarkers for prostate cancer diagnosis and risk assessment has been reissued and will be effective March 4, 2026. This policy update affects coverage and billing for prostate cancer diagnostic biomarker testing under Medicare Advantage plans.
Action Required
Before March 4, 2026: Billing team should review the full policy MA06.036 to understand coverage criteria for protein biomarker testing for prostate cancer diagnosis and risk assessment. Update billing protocols and prior authorization requirements as specified in the complete policy document once available.